Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05767398 · ClinicalTrials.gov registry record · Phase 1
Bioequivalence of a Zanubrutinib Tablet Compared to Capsules in Healthy Adult Participants
A Phase 1 study, sponsored by BeiGene.
- Completed
- Registry status
- Phase 1
- Development phase
- 58
- Enrollment target
NCT05767398 is a Phase 1 study that has completed, run by BeiGene. The registered enrollment target is 58 participants.
The verdict
NCT05767398, a Phase 1 study, has completed, sponsored by BeiGene.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 58 participants
- Enrollment target
Study Summary
Study to determine the bioequivalence of a zanubrutinib tablet compared to capsules in healthy adult participants.
Interventions
- DRUG Zanubrutinib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 58 participants |
| Start Date | 2023-03-07 |
| Est. Completion | 2023-04-28 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05767398
The ClinicalTrials.gov registry entry for NCT05767398 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 58 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is BeiGene, which has 65 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Zanubrutinib is the first listed.
NCT05767398 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05767398 about?
NCT05767398 is a clinical study titled "Bioequivalence of a Zanubrutinib Tablet Compared to Capsules in Healthy Adult Participants". Study to determine the bioequivalence of a zanubrutinib tablet compared to capsules in healthy adult participants.
What is the current status of trial NCT05767398?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 58 participants. The study started on 2023-03-07. Estimated completion is 2023-04-28.
What interventions are being tested in trial NCT05767398?
The interventions under investigation include: Zanubrutinib (DRUG).
Who is sponsoring clinical trial NCT05767398?
This trial is sponsored by BeiGene, which has 65 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.